Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Study predicts human doses of RVT-801 for treating Farber disease

Feb. 14, 2018

EC approves Diurnal's Alkindi as replacement therapy for pediatric adrenal insufficiency

Feb. 13, 2018

Clenbuterol improves muscle function in patients with late-onset Pompe disease

Feb. 13, 2018

Audentes Therapeutics begins dosing in phase I/II VALENS study

Feb. 13, 2018

First-in-human results presented for SBC-103 in children with MPS IIIB

Feb. 13, 2018

SGSH gene therapy shows biological activity in phase I/II MPS type III A trial

Feb. 13, 2018

FDA grants priority review to migalastat NDA

Feb. 13, 2018

Dare Bioscience obtains license to Strategic Science & Technologies' SST-6007

Feb. 13, 2018

FDA awards orphan drug status to Abeona's ABO-202

Feb. 13, 2018

Roivant and Poxel sign development and license agreement for imeglimin

Feb. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...